On June 18, we offered a final webinar in a three part series that explains the process in Canada from discovering a new drug to getting the drugs paid for or covered by various public and private insurance plans. The webinars presented by the expert speakers provided...
In this three part series, we brought in experts to explain the process to bring a drug to market, such as discovering a potential drug in a lab, running clinical trials in humans, getting a drug approved by Health Canada to getting the drug covered by public and...
This document provides an overview of the public drug plans in each province in alphabetical order. Read more on who qualifies for the program, what the deductible, premium and co payment is, who pays for medications first and where additional information can be...
There are a number of biosimilar medications available to treat people with arthritis in Canada. A biosimilar is a biologic drug that is highly similar to a biologic drug that was already authorized for sale. Health Canada has recently updated its fact sheet on...
We have developed this resource to help you manage taking methotrexate, an important medication for people who live with different types of arthritis.
With healthcare providers, we have developed this resource for you about methotrexate.
This resource is part of a number of projects under the theme of TEAM (Together Enhancing Arthritis Management). By the end of the session, you will: Understand the goals of treatment in inflammatory arthritis Understand the role of medications in treating...
CAPA heard about Manulife's DrugWatch Program and wanted to fully understand it and provide you with information about it. Below is an article that we have developed on the Program and how it may affect you. We thank our colleagues at Manulife, Lisa...
Have you considered or been approached about switching from a biologic to a biosimilar for helping manage your inflammatory arthritis? This video about biosimilars may help you understand more about biologics and biosimilars and to have a conversation with your...
Are you considering talking to your healthcare provider about biosimilars or has your healthcare provider talked to you already about biosimilars? We have put together some questions that might be helpful to be part of a conversation with your healthcare provider about biosimilars and brand name biologics.
Clinical trials show that COVID-19 vaccines are safe and effective. Should I get vaccinated? CRA, with input from CAPA, designed a Decision Aid tool to help those living with an autoimmune disease to decide with their healthcare provider what best would work for them.
We have developed this resource to help you manage taking methotrexate, an important medication for people who live with different types of arthritis.
With healthcare providers, we have developed this resource for you about methotrexate.
Medical cannabis is an important topic for people who live with arthritis and who are looking for ways to relieve their pain. CAPA's position paper is here, and you may also wish to learn more about this topic using resources provided by the Arthritis...
CAPA is continuously updating this page on biosimilars (also called subsequent entry biologics or SEBs). We have recently updated our position paper and also created a video to help you understand this type of medication.
Are you wondering what is health technology assessment (HTA)? CAPA provided input to Envision Pharma, a medical communications company, as they have developed the infographic on Health Technology Assessment. The purpose of this document is to provide a...
We know there can be a lot of questions about the flu vaccine when you live with inflammatory arthritis. As people who live with arthritis, we put together some questions that our Medical Advisory Committee has answered for you here. Nous savons que le...
CAPA has been working with Clinical Trials Ontario to develop information resources about clinical trials that are easy to understand and that can help people who wish to learn more about clinical trials or who may even wish to find a clinical trial.
You have heard about clinical trials, but are unsure about what they are, and what it means to participate. This infographic has been developped by Clinical Trials Ontario to help navigate. It provides an explanation of what clinical trials are, the...
Clinical trials are a key part of the research process. If you’re thinking about participation in a clinical trial, CAPA encourages you to read up on clinical trials and make a decision that is right for you. Below are some resources to help get you started where CAPA has been involved.
In Fall 2018, CAPA provided patient input to a proposed protocol by CADTH requiring triple csDMARD therapy for treating moderate to severe rheumatoid arthritis. To provide a more complete response, CAPA worked collaboratively to provide a joint response on the...
The Canadian Agency for Drugs and Technologies in Health (CADTH) is an independent, not for profit agency that is funded by Canada’s federal, provincial, and territorial governments, and which provides evidence-based information to health care leaders and policy...
Medical cannabis is an important topic for people who live with arthritis and who are looking for ways to relieve their pain. CAPA's position paper is here, and you may also wish to learn more about this topic using resources provided by the Arthritis...
The Canadian Arthritis Patient Alliance (CAPA) works with various groups in the arthiritis community to ensure the voice of people living with arthritis is heard and to bring you up-to-date information on issues that affect the arthritis community. We work with healthcare professionals, health organizations, clinicians, industry, health charities, researchers, and various levels of government.
We keep Canadian people living with arthritis and their support groups understand more about their disease and have a voice in managing it.
English 
Français du Canada